India Globalization Capital, Inc. (NYSE:IGC) produced a 88.53% rally since recording the worst price of $0.19. Thanks to the latest 5.38% increase, it now trades at $0.36. Throughout the trading on 9/12/2017, the share price floated between $0.34 and $0.37. This company shares are -100% up from its target price of $0 and the current market capitalization stands at $9.83M. The recent change has given its price a -3.96% deficit over SMA 50 and -55.22% deficit over its 52-week high. The stock witnessed -5.74% declines, -18.59% declines and 10.22% gains for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found IGC’s volatility during a week at 7.14% and during a month it has been found around 8.52%.

India Globalization Capital, Inc. 13F Filings

At the end of June reporting period, 6 institutional holders increased their position in India Globalization Capital, Inc. (NYSE:IGC) by some 387,876 shares, 1 decreased positions by 67,680 and 2 held positions by 105,500. That puts total institutional holdings at 561,056 shares, according to SEC filings. The stock grabbed 3 new institutional investments totaling 24,351 shares.

The rally comes after the company provided an update on compelling in vitro data compiled from genetically engineered cell lines, confirmed by Dr. Chuanhai Cao, an IGC Senior Advisor and Associate Professor of Pharmaceutical Sciences at USF’s College of Pharmacy, which shows that at varying concentrations of THC, the production of Aβ40 protein decreases by as much as 50% over a 48-hour period.

It is believed that Alzheimer’s disease is caused by two types of legions in the cerebral cortex and hippocampus: 1) senile plaque composed of amyloid beta peptides (Aβ plaque), and 2) neurofibrillary tangle, composed of highly phosphorylated Tau protein. Amyloid Protein Precursor (APP), on the surface of neurons, is normally cleaved by enzymes to free up Aβ peptide composed of 36-43 amino acids that is then cleared by the body.

In patients with Alzheimer’s, an imbalance causes Aβ to be unregulated, resulting in the abnormal buildup into insoluble fibroles depositing as senile plaques. Aβ monomers aggregate to form oligomers and then into fibril Aβ. It is believed that extracellular misfolded oligomers are toxic to nerve cells.

The summary data indicates that at a 25nM THC concentration, Aβ40 production decreased by 30% over a 6-hour period; 35% over a 24-hour period; and 40% over a 48-hour period. At a 2.5 μM concentration of THC, Aβ40 production decreased by 30% over a 6-hour period; 40% over a 24-hour period; and 55% over a 48-hour period.

Previous articleRed Hot Stocks: Buy, Sell, or Hold? – Intel Corporation (INTC), Juniper Networks, Inc. (JNPR)
Next articleEyegate Pharmaceuticals, Inc. (EYEG) loses confidence of 4 hedge fund managers